ImmunityBio, Inc. (IBRX) reported initial data indicating that a single subcutaneous injection of the company's COVID-19 vaccine candidate in healthy phase 1 clinical study participants stimulated the generation of T cells that are reactive to the spike and nucleocapsid protein antigens delivered by the vaccine. The mean T cell levels seen in the vaccinated participants were equivalent to those for patients recovered from infection by the virus.
The company noted that 14-16 days after the single dose, the mean level of T cells generated in response to the hAd5 S+N T cell vaccine were ten times higher for N specific T cells. By day 21, both S and N T cell responses achieved levels ten times higher as compared to pre-vaccination levels, the company noted.
"These data further validate the path we have taken in designing our vaccine candidate to target both the S and N proteins in order to increase T cell responses," said Patrick Soon-Shiong, Founder and Executive Chairman of ImmunityBio.
For comments and feedback contact: editorial@rttnews.com
Business News